Israel's Atox Bio raises $30 mln in Arix Bioscience-led round

Shutterstock photo

JERUSALEM, Dec 4 (Reuters) - Israeli biotech firm Atox Bio said on Monday it raised $30 million to further develop its leading product as a kidney treatment, in a fundraising round led by U.K.-based Arix Bioscience.

Atox Bio hopes to push forward with clinical development of its immune system treatment Reltecimod for Acute Kidney Injury, which it said is a major unmet clinical need in critically ill patients with severe infections.

Reltecimod is already being studied in a phase 3 clinical study in patients with Necrotizing Soft Tissue Infections, also known as flesh eating bacteria. Atox Bio said it plans to start a phase 2 study in Acute Kidney Injury in 2018.

Let's block ads!(Why?)

Read Again Israel's Atox Bio raises $30 mln in Arix Bioscience-led round : http://ift.tt/2kl0eFM

Let's block ads! (Why?)